Coherus Rolls Out YUSIMRY At $995 Per Carton In US

RTTNews | Před 850 dny
Coherus Rolls Out YUSIMRY At $995 Per Carton In US

(RTTNews) - Coherus BioSciences, Inc. (CHRS) announced Monday that YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors.

The pricing represents a discount of more than 85% to Humira (adalimumab), currently priced at $6,922 per carton of two pens.

YUSIMRY is presented in a state-of-the-art autoinjector and includes Coherus' proprietary non-stinging, citrate-free formulation and a 29-gauge needle.

YUSIMRY, approved in 2021 by the U.S. Food and Drug Administration, is a tumor necrosis factor blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

YUSIMRY Solutions - Coherus' patient services platform - will ensure improved access and a fast and seamless experience as patients start or switch to YUSIMRY treatment based on a determination by their healthcare provider.

read more
Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus BioSciences, Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.
RTTNews | Před 1212 dny
Japanese Market Sharply Higher

Japanese Market Sharply Higher

Extending the gains in the previous two sessions, the Japanese market is sharply higher on Friday, despite the broadly negative cues from Wall Street overnight. The Nikkei 225 is moving above the 52,200 level to fresh all-time highs, with gains in index heavyweights, exporters and technology stocks partially offset by weakness in automakers and financial stocks.
RTTNews | Před 27 minutami
Australian Market Notably Higher

Australian Market Notably Higher

The Australian stock market is trading notably higher on Friday, snapping a three-session losing streak, despite the broadly negative cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,900 level, with gains in gold miners and financial stocks.
RTTNews | Před 1 h 1 min
Swiss Market Settles Slightly Down

Swiss Market Settles Slightly Down

The Switzerland market ended slightly down on Thursday, after languishing in the red almost right through the day's session, with investors reacting to corporate earnings updates, and a report showing signs of an improved outlook in the Swiss economy.
RTTNews | Před 7 h 23 min
ECB Holds Interest Rates Steady Amid Uncertain Outlook

ECB Holds Interest Rates Steady Amid Uncertain Outlook

The European Central Bank maintained its key interest rates unchanged for a third policy session in a row on Thursday, as expected, as policymakers assessed that the outlook was broadly unchanged, but still uncertain due to global trade conflicts and geopolitical tensions.
RTTNews | Před 11 h 25 min
Eurozone GDP Growth Beats Expectations

Eurozone GDP Growth Beats Expectations

The euro area economy expanded at a faster pace in the third quarter as France and Spain reported strong growth, while Germany and Italy experienced stagnation, amid a highly uncertain outlook due to the ongoing trade policies and political instability. Gross domestic product climbed 0.2 percent sequentially in the September quarter, preliminary flash estimate from Eurostat showed on Thursday.
RTTNews | Před 12 h 10 min